Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 clinical trials
Also written JNJ-101556143.
How each study uses Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JNJ-101556143
- 2
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT06800313Written as JNJ-101556143 Formulation 1
- A Study of JNJ-101556143 in Participants With Metastatic Prostate CancerRecruitingPhase 2Janssen Research & Development, LLCNCT07832292Written as JNJ-101556143
- A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate CancerRecruitingPhase 3Janssen Research & Development, LLCNCT07906717Written as JNJ-101556143
Given beside what is tested · 2 — Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 is usual care or a partner of the new treatment
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT06095089Written as JNJ-101556143
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as JNJ-101556143
What changed recently
From the registry's own updates since Oct 15, 2026.